University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Katherine Van Loon, MD, MPH

Katherine Van Loon, MD, MPH

Associate Professor of Clinical Medicine, UCSF; Director, Global Cancer Program, Helen Diller Family Comprehensive Cancer Center

Cancer Center Program Memberships

Cancer Control

Education

Duke University    B.S.    05/00    Biology
Yale University    M.P.H.    05/02    Health Policy
Medical College of Georgia    M.D.    05/06    Medicine
Beth Israel Deaconess, Harvard Medical School    Intern    06/07    Internal Medicine
Beth Israel Deaconess, Harvard Medical School    Resident    06/09    Internal Medicine
University of California, San Francisco    Fellow    06/12    Oncology
 


Professional Experience

  • 2012-present
    Assistant Clinical Professor, Division of Hematology/Oncology, UCSF
  • 2011-2012
    Non-ACGME Fellow, Division of Hematology/Oncology, UCSF
  • 2009-2011
    ACGME Fellow, Division of Hematology/Oncology, UCSF

Honors & Awards

  • 2013
    NANETS Clinical Investigator Scholarship
  • 2013
    AHRQ K12 PARTNERS Program Scholar
  • 2012
    Young Investigator Award, ASCO Conquer Cancer Foundation
  • 2008
    Yale/Johnson & Johnson Physician Scholar in International Health, South Africa
  • 2008
    Nomination by Harvard Medical School Class of 2008 for Excellence in Teaching
  • 2002
    Dean’s Prize for Outstanding MPH Thesis, Yale University
  • 2001
    Weinerman Fellowship for Social Justice, Yale University
  • 2000
    Graduation with Distinction in Biology, Duke University
  • 2000
    Howard Hughes Undergraduate Fellowship in Neuroscience, Duke University

Selected Publications

  1. Innocenti F, Owzar K, Jiang C, Etheridge AS, Gordân R, Sibley AB, Mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, Yeh JJ, Van Loon K, McLeod H, Ratain MJ, Kindler HL, Venook AP, Nakamura Y, Kubo M, Petersen GM, Bamlet WR, McWilliams RR. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
    View on PubMed
  2. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. J Gastrointest Cancer. 2018 Jul 30.
    View on PubMed
  3. Snyder RA, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, Van Loon K, You YN, Kozower BD, Greenberg CC, Schrag D, Venook A, McKellar D, Winchester DP, Chang GJ. Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer. JAMA. 2018 May 22; 319(20):2104-2115.
    View on PubMed
  4. Ursem C, Atreya CE, Van Loon K. Emerging treatment options for BRAF-mutant colorectal cancer. Gastrointest Cancer. 2018; 8:13-23.
    View on PubMed
  5. Van Loon K, Mwachiro MM, Abnet CC et al.. The African Esophageal Cancer Consortium: A Call to Action. Journal of Global Oncology. 2018.
    View on PubMed
  6. Murphy G, McCormack V, Abedi-Ardekani B, Arnold M, Camargo MC, Dar NA, Dawsey SM, Etemadi A, Fitzgerald RC, Fleischer DE, Freedman ND, Goldstein AM, Gopal S, Hashemian M, Hu N, Hyland PL, Kaimila B, Kamangar F, Malekzadeh R, Mathew CG, Menya D, Mulima G, Mwachiro MM, Mwasamwaja A, Pritchett N, Qiao YL, Ribeiro-Pinto LF, Ricciardone M, Schüz J, Sitas F, Taylor PR, Van Loon K, Wang SM, Wei WQ, Wild CP, Wu C, Abnet CC, Chanock SJ, Brennan P. International cancer seminars: a focus on esophageal squamous cell carcinoma. Ann Oncol. 2017 Sep 01; 28(9):2086-2093.
    View on PubMed
  7. Mmbaga, EJ, Deardorff, KV, Mushi, B, Mgisha, W, Merritt, M, Hiatt, RA, Mwaiselage, J, Zhang, L, Van Loon, K. Characteristics of Esophageal Cancer Cases in Tanzania. Journal of Global Oncology. 2017.
    View on PubMed
  8. Mulvey CK, Van Loon K, Bergsland EK, Masharani U, Nakakura EK. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Pancreas. 2017 03; 46(3):416-426.
    View on PubMed
  9. Atreya CE, Greene C, McWhirter RM, Ikram NS, Allen IE, Van Loon K, Venook AP, Yeh BM, Behr SC. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. J Natl Compr Canc Netw. 2016 12; 14(12):1536-1543.
    View on PubMed
  10. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874.
    View on PubMed
  11. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol. 2016 12; 39(6):614-618.
    View on PubMed
  12. Zukotynski K, Jadvar H, Hope T, Subramaniam RM, Van Loon K, Varma M, Niederkohr RD. SNMMI Comment on the 2016 Society of Surgical Oncology "Choosing Wisely" Recommendation on the Use of PET/CT in Colorectal Cancer. J Nucl Med. 2017 Jan; 58(1):11-12.
    View on PubMed
  13. Ursem C, Van Loon K, Venook A. Adjuvant Therapy Trials. Cancer J. 2016 May-Jun; 22(3):196-8.
    View on PubMed
  14. Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Mar 15; 22(6):1348-55.
    View on PubMed
  15. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8.
    View on PubMed
  16. Cheng ML, Zhang L, Borok M, Chokunonga E, Dzamamala C, Korir A, Wabinga HR, Hiatt RA, Parkin DM, Van Loon K. The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot? Cancer Epidemiol. 2015 Apr; 39(2):143-9.
    View on PubMed
  17. Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect. 2015 Mar; 4(1):9-17.
    View on PubMed
  18. Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O'Reilly EM, Fuchs C, Innocenti F, Venook AP. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). J Natl Cancer Inst. 2014 Aug; 106(8).
    View on PubMed
  19. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.
    View on PubMed
  20. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014 Jun 15; 120(12):1780-6.
    View on PubMed

Go to UCSF Profiles, powered by CTSI